Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 16 June 2015 | By Michael Mezher
The European Medicines Agency (EMA) is piloting a new initiative to offer early meetings with companies to foster discussions about their pediatric development strategies for new medicines.
Companies are often reluctant to conduct clinical studies in children due to ethical concerns and fear of adverse events during trials. However, conducting clinical research on children is critical to determining whether drugs are safe and effective in pediatric populations.
To ensure adequate research is conducted in pediatric populations, companies developing medicines in the EU are required to complete a paediatric investigation plan (PIP).
The requirements for a PIP are found in Regulation (EC) No 1901/2006 and Regulation (EC) No 1902/2006, known collectively as the Paediatric Regulation. However, while companies are generally required to conduct studies in pediatric populations, waivers can be granted for specific products and product classes:
Additionally, deferrals can be granted if, "it is appropriate to conduct studies in adults prior to initiating studies in the paediatric population or when studies in the paediatic population will take longer to conduct than studies in adults."
In the years since the Paediatric Regulations went into effect, EMA says it has "identified a number of issues which often delay the paediatric development" of new products. In turn, these delays either result in slower access to medicines for children, or authorized medicines that lack safety and dosage information for pediatric populations.
EMA is looking to address these delays by offering companies "free-of-charge early paediatric interaction meetings." Through these meetings, EMA hopes to iron out potential issues before a company submits a PIP.
EMA says it will pilot the initiative until June 2016 and will use the experience gained in the pilot to either continue or modify the initiative. The agency will be limited in how many early pediatric meetings it can facilitate through the pilot, so "medicines for rare diseases or high paediatric need" will be prioritized."
Tags: PIP, Pediatric Investigation Plan, Paediatric Investigation Plan
Regulatory Focus newsletters
All the biggest regulatory news and happenings.